Tivozanib hydrochloride hydrate is a potent and selective and orally activeVEGFRtyrosine kinaseinhibitor withIC₅₀of 0.21, 0.16, 0.24 nM forVEGFR-1, VEGFR-2,VEGFR-3, respectively. Tivozanib hydrochloride hydrate inhibits angiogenesis and vascular permeability in tumor tissues and shows antitumor activity. Tivozanib hydrochloride hydrate has the potential for the research of metastatic renal cell carcinoma (RCC)^[1][2][3].

Tivozanib hydrochloride hydrate inhibits the phosphorylation of VEGFR-1, VEGFR-2 and VEGFR-3^[2].

Tivozanib hydrochloride hydrate (1 mg/kg; p.o.; 14 days) suppresses the development of CNV lesions and leds to a significant regression of established CNV, reducing the affected areas by 67.7%^[4].

509.34

Solid

C₂₂H₂₂Cl₂N₄O₆

682745-41-1

Room temperature in continental US; may vary elsewhere.

4°C, sealed storage, away from moisture and light

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

DMSO : 250 mg/mL(490.83 mM;Need ultrasonic)

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month (sealed storage, away from moisture and light)。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。